Produktname:4-chloro-6-iodo-7H-pyrrolo[2,3-d]pyrimidine

IUPAC Name:4-chloro-6-iodo-7H-pyrrolo[2,3-d]pyrimidine

CAS:876343-10-1
Molekulare Formel:C6H3ClIN3
Reinheit:95%+
Katalognummer:CM104043
Molekulargewicht:279.47

Packungseinheit Verfügbarer Vorrat Preis($) Menge
CM104043-5g in stock ǺœƩ
CM104043-10g in stock ȋƚş
CM104043-25g in stock œƚƩ

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

   refresh    

Produkt-Details

CAS-Nr.:876343-10-1
Molekulare Formel:C6H3ClIN3
Schmelzpunkt:-
SMILES-Code:ClC1=C2C=C(I)NC2=NC=N1
Dichte:
Katalognummer:CM104043
Molekulargewicht:279.47
Siedepunkt:
Mdl-Nr.:MFCD11518919
Lagerung:-20°C

Category Infos

Pyrrolopyrimidines
Fusion heterocyclic compounds have various biological activities, such as anticancer, antibacterial, antifungal and anti-inflammatory, and thus have been widely used in the field of medicinal chemistry. Pyrrolopyrimidines are a major class of fused heterocyclic compounds. Compared with single pyrrole and pyrimidine cores, pyrrolopyrimidines have more diverse and effective pharmacological characteristics as fusion scaffolds.

Column Infos

BMF-219
Biomea Fusion’s BMF-219 demonstrates promising early signs of clinical activity, with its ability to achieve durable and sustained complete responses (CRs) and minimal residual disease negativity (MRD-neg) in patients with acute myeloid leukemia (AML). Biomea Fusion recently presents this First Complete Responder from Ongoing Phase I Study at the 2023 ASH.
BMF-219 is the first and only covalent menin inhibitor in clinical development for AML, ALL, DLBCL, MM and CLL. Additionally, BMF-219 is being explored for its potential to regenerate insulin-producing beta cells as a treatment of type 1 diabetes.

Related Products